Andrew J. Schwab

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
San Francisco, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Andrew J. Schwab
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Andrew J. Schwab

Form 4 holding Director, 10%+ Owner

Pear Therapeutics, Inc.

Security class
Class A Common Stock
Shares / value
14,648,641
Estimated value
Report date
03 Dec 2021
Price
Ownership
by 5AM Ventures IV, L.P.
Form 4 holding Director, 10%+ Owner

Pear Therapeutics, Inc.

Security class
Class A Common Stock
Shares / value
3,372,769
Estimated value
Report date
03 Dec 2021
Price
Ownership
by 5AM Opportunities I, L.P.
Form 4 holding Director

Camp4 Therapeutics Corp

Security class
Pre-Funded Warrant (Right to Buy)
Shares / value
3,179,558
Estimated value
Report date
03 Aug 2026
Price
Ownership
By 5AM Ventures VII, L.P.
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Pear Therapeutics, Inc.

Security class
Class A Common Stock
Shares / value
610,361
Estimated value
Report date
03 Dec 2021
Price
Ownership
by 5AM Co-Investors IV, L.P.
Form 4 holding Director

Skye Bioscience, Inc.

Security class
Stock Option (Right to Buy)
Shares / value
75,000
Estimated value
Report date
31 Mar 2026
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director, 10%+ Owner

Enliven Therapeutics, Inc.

Security class
Stock Option (right to buy)
Shares / value
27,567
Estimated value
Report date
23 Feb 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Camp4 Therapeutics Corp

Security class
Series A Prime Preferred Stock
Shares / value
0
Estimated value
Report date
15 Oct 2024
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount
Form 4 holding Director

Camp4 Therapeutics Corp

Security class
Series B Preferred Stock
Shares / value
0
Estimated value
Report date
15 Oct 2024
Price
Ownership
Indirect
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Andrew J. Schwab

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .